Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Evan Feinman, the former director of the Broadband Equity, Access, and Deployment Program, or BEAD, which provides grants to ...

Sawyer Hawks, a Vanderbilt baseball transfer, is guided by his late mother's memory and by the community that helped raise ...

Trump’s invocation is a doubling down upon his mass-deportation mission, and setting up a crisis by openly defying the courts ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

Graft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

TransMedics Group operates an organ transplant ecosystem under which it offers patented technology to preserve and mobilize organs, services that support transplant centers and medical teams, and a ...